DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Frequently asked questions
What sector does DexCom Inc. (D1EX34) operate in?
DexCom Inc. belongs to the Healthcare sector and operates in the Medical Devices industry.
What is DexCom Inc. (D1EX34) current stock price?
As of the latest data, DexCom Inc. stock price is R$9.47, with a previous close of R$9.28. DexCom Inc. gained R$0.19 in the last trading session, representing a 2.05% increase.
What is DexCom Inc. (D1EX34) current market capitalization?
DexCom Inc. market cap is approximately 178.68 billion.
What is DexCom Inc. (D1EX34) Earnings Per Share (EPS)?
The trailing EPS is R$0.26.
What is DexCom Inc. (D1EX34) Price-to-Earnings (P/E) ratio?
DexCom Inc. current P/E ratio is 36.42.
Does DexCom Inc. (D1EX34) pay dividends?
No. DexCom Inc. does not pay a dividend.
What is DexCom Inc. (D1EX34) beta (volatility) score?
DexCom Inc. has a beta of 1.410, suggesting it is more volatile than the market.
